$300 Billion Orphan Drugs Market Opportunity Assessment, 2026 - Insights Into Clinical Trials (900+ Drugs), Patents and Guidelines

DUBLIN, March 18, 2020 /PRNewswire/ -- The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.

• Global Orphan Drug Market Opportunity: US$ 300 Billion
• US Dominates Global Orphan Drug Market: 50% Market Share
• US Orphan Drug Opportunity To Surpass: US$ 150 Billion
• Global Orphan Drug Clinical Insight: More Than 900 Drugs
• Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
• Oncology To Dominate Orphan Drug Development: 35% Share
• FDA & EMA Regulations For Orphan Drugs
• Orphan Drug Designation Criteria & Reimbursement Policy by Country

This report discusses about the recent trends and opportunities that the orphan drug market has brought into the pharmaceutical sector. The information related to the current status of the evolving market strategies and ongoing clinical studies by the companies involved in development of the orphan drugs is elaborately discussed in the report.

The research report shares the information related to drugs that have been successfully designated as orphan drugs by respective approval authorities, with an exclusive insight on clinical uniqueness and patent information. In addition to the commercial information, the report brings a deep insight about the efforts that have been put to establish the market as it is now.

Global Orphan Drug Market is Estimated to Witness 150% Market Growth by 2026, Compared to 2018

Orphan drugs market has been recently recognized as a promising therapeutic market as the diseases that are covered under the market are life-threatening diseases. The FDA & EMA have designated a drug as orphan drug for which the cases in the US are less than 0.2 Million and not more than 5 in 10,000 people across the EU. Earlier the orphan drug segment was overlooked by the big pharmaceutical companies as developing and marketing of these drugs was considered not so profitable. Majority of the research and development activities related to orphan drugs were done by small size pharmaceutical firms and less than 25% of the orphan drugs were being researched and developed by the big firms.

The enactment of 1983 US Orphan Drug Act, as well as similar Acts in 1991 in Singapore, 1993 in Japan, 1997 in Australia and in 2000 by the European Union led to rapid transformation of global orphan drug market landscape which was earlier neglected by the multiple stake holders of the pharmaceutical industry. The structured regulatory and policy framework favoring the research and development of orphan designated drugs resulted in the much needed thrust for the development of global orphan drug market. These laws allowed the various financial incentives, market exclusivity, patent protection, high price allotment and government grants, which resulted in favorable economic environment for the entry of big pharmaceutical companies in the orphan drug segment.

The entry of mid and large size pharmaceutical companies helped in the speeding up the clinical research activities related to orphan drugs. The number of clinical trials increased drastically in last 10 years to more than 500 for orphan drugs as compared to few hundred trials in beginning of 21st century. Currently, more than 400 orphan designated drugs are commercially available in the marketed and close to 1000 drugs are undergoing clinical trials. The number of clinical trials covering the rare diseases has been observed to increase in the recent years with a major participation of the players such as Roche, Celgene, AbbVie, Johnson & Johnson, Shire, Alexion, Novo Nordisk, Sanofi and Bayer. The various major key players and the rising demand of the orphan drugs clearly depicts about the escalation that the market will experience in the future.

The availability of large number of orphan drugs by limited firms provides an excellent fundamental benefit to the emerged market in the present as well as in future. The dynamic interest scenario that has been delivered by the users since its arrival has completely changed the landscape of the market. The drastic change from few users in the past to millions of users till now has been successful in proving the importance of orphan drugs in the market. It is well witnessed from analyzing the market value of orphan drugs that clinicians as well as rare disease patients are now more inclined towards its use, thereby, promoting a form of treatment that is more mainstream.

As per report findings, the orphan drug market is open to serve the globe with an approach that is about to bring a fresh new era for the life threatening diseases. The ongoing clinical research at preclinical and clinical levels and the major trends followed by the regions such as North America and Europe are about to introduce a drastic change in overall scenario of the approach. The market is driven by the anticipation of the players and the huge commercial success that the market has foreseen in few years. The enhancement and the shape that the market has developed since years is about to get evolved as a serious option for rare diseases.

Key Topics Covered

1. What Are Orphan Drugs?

2. Global Orphan Drug Designation Criteria
2.1 US
2.2 Europe
2.3 Asia & Australia
2.3.1 Japan
2.3.2 Taiwan
2.3.3 South Korea
2.3.4 Australia

3. Market Exclusivity & Patent Protection for Orphan Drugs

4. Global Orphan Drug Reimbursement Policy
4.1 US
4.2 Europe
4.3 Asia

5. Global Orphan Drug Market Opportunity Insight, 2026
5.1 Global Orphan Drug Sales Opportunity
5.2 Market by Class Variation
5.3 Market by Therapeutic Application
5.4 Market by Regions

6. FDA Regulation for Clinical Trials Orphan Designated Drugs
6.1 Content & Format Of A Request For Written Recommendations
6.2 Provision For Granting & Refusing Written Recommendations
6.3 Content And Format Of A Request For Orphan Drug Designation
6.4 Verification Of Orphan Drug Status & Resident Agent For Foreign Sponsor
6.5 Timing Of Requests For Orphan Drug Designation & Designation Of Already Approved Drugs
6.6 Deficiency Letters And Granting Orphan Drug Designation
6.7 Refusal To Grant Orphan Drug Designation
6.8 Amendment & Change In Ownership To Orphan Drug Designation
6.9 Publication & Revocation Of Orphan Drug Designations
6.10 Annual Reports Of Holder Of Orphan Drug Designation
6.11 Scope & FDA Recognition Of Orphan Drug Exclusive Approval
6.12 Protocols for Investigations & Availability of Information

7. EMA Regulations for Clinical Trials of Orphan Designated Drugs
7.1 Committee for Orphan Medicinal Products
7.2 How to Apply for Orphan Designation in Europe
7.3 Marketing Authorization & Market Exclusivity
7.4 Transferring An Orphan Designation To Another Sponsor
7.5 Mandatory Submission Of Annual Report On Development
7.6 Incentives For Micro, Small And Medium-Sized Enterprises
7.7 Fee Reductions For Designated Orphan Medicinal Products
7.8 Procedure for Orphan Designation & Incentives for R&D (Regulation (EC) No 141/2000 )

8. Asian Regulations for Clinical Trials of Orphan Designated Drugs
8.1 Taiwan Rare Disease and Orphan Drug Act
8.2 Japan Orphan Drug Regulation

9. Global Orphan Clinical Pipeline Overview
9.1 By Company
9.2 Drug Class
9.3 Formulation
9.4 Indication
9.5 Region
9.6 Priority Status
9.7 Patient Segment
9.8 By Phase

10. Unknown Phase - Orphan Drugs Clinical Pipeline By Company, Country & Indication
10.1 Overview
10.2 Clinical Pipeline Insight

11. Research Phase - Orphan Drugs Clinical Pipeline By Company, Country & Indication

12. Preclinical Phase - Orphan Drugs Clinical Pipeline By Company, Country & Indication

13. Clinical Phase - Orphan Drugs Clinical Pipeline By Company, Country & Indication

14. Phase-I - Orphan Drugs Clinical Pipeline By Company, Country & Indication

15. Phase-I/II - Orphan Drugs Clinical Pipeline By Company, Country & Indication

16. Phase-II - Orphan Drugs Clinical Pipeline By Company, Country & Indication

17. Phase-II/III - Orphan Drugs Clinical Pipeline By Company, Country & Indication

18. Phase-III - Orphan Drugs Clinical Pipeline By Company, Country & Indication

19. Preregistration - Orphan Drugs Clinical Pipeline By Company, Country & Indication

20. Registered - Orphan Drugs Clinical Pipeline By Company, Country & Indication

21. Marketed Orphan Drugs Clinical Insight By Company, Country & Indication

22. Competitive Landscape
22.1 AOP Orphan
22.2 Agenus
22.3 Alexion
22.4 Bristol Myers Squibb
22.5 Biogen Idec
22.6 Celgene
22.7 Eli Lilly
22.8 Genethon
22.9 Genzyme Corporation
22.10 Glaxosmithkline
22.11 Merck
22.12 Novartis Pharmaceuticals
22.13 Orphan Europe
22.14 Pfizer
22.15 Prosensa
22.16 Rare Disease Therapeutics
22.17 Roche
22.18 Sanofi
22.19 Shire
22.20 Teva Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/r/7oklzv

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com